



ANDA 200222

Teva Pharmaceuticals USA
Attention: Philip Erickson, R.Ph.
Vice President, Regulatory Affairs
1090 Horsham Road
P.O. Box 1090
North Wales, PA 19454

Dear Sir:

This is in reference to your abbreviated new drug application (ANDA) dated August 31, 2009, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (the Act), for Linezolid Injection, 2 mg/mL, packaged in 600 mg/300 mL Single-use Flexible Plastic Containers.

Reference is also made to your amendments dated June 11, 2010; November 10, and November 29, 2011; and February 27, and April 20, 2012. We also acknowledge receipt of your correspondences dated December 3, and December 4, 2009; October 1, 2010; and June 21, 2012, addressing the patent issues associated with this ANDA.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the ANDA is approved, effective on the date of this letter. The Division of Bioequivalence has determined your Linezolid Injection, 2 mg/mL, packaged in 600 mg/300 mL Single-use Flexible Plastic Containers to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug (RLD), Zyvox Injection, 2 mg/mL, packaged in 600 mg/300 mL Single-use Flexible Plastic Containers of Pharmacia and Upjohn Co. (Pharmacia).

The RLD upon which you have based your ANDA, Pharmacia's Zyvox Injection, 2 mg/mL, packaged in 600 mg/300 mL Single-use Flexible Plastic Containers is subject to periods of patent protection. As noted in the agency's publication titled

Approved Drug Products with Therapeutic Equivalence Evaluations (the "Orange Book"), U.S. Patent Nos. 5,688,792 (the '792 patent) and 6,559,305 (the '305 patent) are scheduled to expire on May 18, 2015, and July 29, 2021, respectively (with pediatric exclusivity added).

With respect to each of these patents, your ANDA contains paragraph IV certifications under section 505(j)(2)(A)(vii)(IV) of the Act stating that each patent is invalid, unenforceable, or will not be infringed by your manufacture, use, or sale of Linezolid Injection, 2 mg/mL, packaged in 600 mg/300 mL Single-use Flexible Plastic Containers under this ANDA. You have notified the agency that Teva Pharmaceuticals USA (Teva) complied with the requirements of section 505(j)(2)(B) of the Act, and that litigation was initiated against Teva for infringement of the '792 patent within the statutory 45-day period in the United States District Court for the District of Delaware [Pfizer Inc., et al. v. Teva Parenteral Medicines, Inc., et al., Civil Action No. 10-0037]. You have further notified the Agency that the case has been dismissed.

With respect to 180-day generic drug exclusivity, we note that Teva was the first ANDA applicant for Linezolid Injection, 2 mg/mL, packaged in 600 mg/300 mL Single-use Flexible Plastic Containers to submit a substantially complete ANDA with a paragraph IV certification. Therefore, with this approval, Teva may be eligible for 180 days of generic drug exclusivity for Linezolid Injection, 2 mg/mL, packaged in 600 mg/300 mL Single-use Flexible Plastic Containers. This exclusivity, which is provided for under section 505(j)(5)(B)(iv) of the Act, would begin to run from the date of the commercial marketing identified in section 505(j)(5)(B)(iv). The agency notes that Teva failed to obtain tentative approval of this ANDA within 30 months after the date on which the ANDA was filed. See section 505(j)(5)(D)(i)(IV) (forfeiture of exclusivity for failure to obtain tentative approval). The agency is not, however, making a formal determination at this time of Teva's eligibility for 180-day generic drug exclusivity. It will do so only if another paragraph IV applicant becomes eligible for full approval (a) within 180 days after Teva begins commercial marketing of Linezolid Injection, 2 mg/mL, packaged in 600 mg/300 mL Single-use Flexible Plastic Containers, or (b) at any time prior to the expiration of the last listed patent if Teva has not begun commercial marketing. Please submit correspondence to this ANDA informing the agency of the date commercial marketing begins.

Under section 506A of the Act, certain changes in the conditions described in this ANDA require an approved supplemental application before the change may be made.

Please note that if FDA requires a Risk Evaluation & Mitigation Strategy (REMS) for a listed drug, an ANDA citing that listed drug also will be required to have a REMS. See section 505-1(i) of the Act.

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

Promotional materials may be submitted to FDA for comment prior to publication or dissemination. Please note that these submissions are voluntary. If you desire comments on proposed launch promotional materials with respect to compliance with applicable regulatory requirements, we recommend you submit, in draft or mock-up form, two copies of both the promotional materials and package insert directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion
5901-B Amundson Road
Beltsville, MD 20705

We call your attention to 21 CFR 314.81(b)(3) which requires that all promotional materials be submitted to the Office of Prescription Drug Promotion with a completed Form FDA 2253 at the time of their initial use.

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at

<http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical in content to the approved labeling (including the package insert, and any patient package insert and/or Medication Guide that may be required).

Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at

<http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>. The SPL will be accessible via publicly available labeling repositories.

Sincerely yours,

{See appended electronic signature page}

Keith Webber, Ph.D.
Deputy Director
Office of Pharmaceutical Science
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ROBERT L WEST

06/27/2012

Deputy Director, Office of Generic Drugs
for Keith Webber, Ph.D.